In the pharmaceutical industry, ensuring the safety and efficacy of drugs doesn't end with Regulatory approval. Post-market surveillance emerges as a pivotal phase in public health. This blog explores its critical role and the Regulatory compliance measures that pharmaceutical companies must adopt in the post-approval stage.
Good pharmacovigilance practices (GVP) are a set of guidelines established by regulatory authorities to ensure the safety of medicinal products. These guidelines provide a comprehensive framework for monitoring, evaluating, and reporting adverse drug reactions (ADRs). However, there are certain situations where exceptions or modifications to GVP may be necessary.